ReviewSeminars in immunopathology2026
Cytokine-mediated, organ-specific immune modulation and dysregulation of innate lymphocytes in sepsis.
Review in Seminars in immunopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sepsis is a life-threatening condition that is marked by dysregulated host immune responses that can induce multiorgan dysfunction. Recent evidence suggests that this immunopathology involves tissue-resident innate lymphocytes, including innate-lymphoid cells (ILCs) and innate-like lymphocytes (ILLs). This review elucidates the organ-specific roles of the three ILC groups (ILC1s, ILC2s, and ILC3s) and two ILL types (NKT and γδ T cells) in sepsis, particularly their cytokine-mediated functions and cell-cell interactions. The literature shows that in the lungs, ILC2-derived IL-9 and IL-13 mitigate pulmonary inflammation and preserve endothelial integrity but dysregulated ILC2 activation may exacerbate injury. In the heart, ILC2s may mediate cardioprotective effects by inducing IL-13-STAT3 signaling and IL-5-mediated eosinophil recruitment. Kidney-resident ILC2s may promote tissue repair in acute-kidney injury (AKI) but their role in sepsis-associated AKI remains underexplored. In the gut and liver, ILC3s protect from sepsis via IL-22, which promotes barrier integrity, but they can convert into ILC1s, whose IFN-γ contributes to tissue damage. Circulating NK cells may play pathogenic and beneficial roles at different times after sepsis onset. NKT and γδ T cells are respectively protective and pathogenic in the gut and liver, likely through their respective production of IFN-γ and IL-17 A. Thus, ILCs and ILLs play key roles in sepsis and could be potential therapeutic targets. Further research is needed to elucidate their precise contributions in each organ and how time since onset and local and systemic conditions affect these contributions.
Indexed as
Identifiers
41961259What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.